Literature DB >> 22738645

Chemically reducible lipid bilayer coated mesoporous silica nanoparticles demonstrating controlled release and HeLa and normal mouse liver cell biocompatibility and cellular internalization.

Robert A Roggers1, Victor S-Y Lin, Brian G Trewyn.   

Abstract

A controlled release system composed of mesoporous silica nanoparticles with covalently bound dipalmitoyl moieties supporting phosphorylated lipids has been successfully synthesized and characterized. This MSN system demonstrates controlled release of fluorescein molecules under disulfide reducing conditions. Flow cytometry analyses confirm increased biocompatibility of the resulting lipid bilayer MSNs (LB-MSNs) from nonfunctional MSNs. Fluorescently labeled LB-MSNs are examined via confocal fluorescent microscopy ex vivo and were found to enter both normal and cancer cell lines. The LB-MSNs presented here have potential to be used as rapid and diverse functionalized, stable liposome analogues for drug delivery.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22738645     DOI: 10.1021/mp200613y

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  10 in total

Review 1.  The practicality of mesoporous silica nanoparticles as drug delivery devices and progress toward this goal.

Authors:  Robert Roggers; Shrey Kanvinde; Suthida Boonsith; David Oupický
Journal:  AAPS PharmSciTech       Date:  2014-05-29       Impact factor: 3.246

Review 2.  Protocells: Modular Mesoporous Silica Nanoparticle-Supported Lipid Bilayers for Drug Delivery.

Authors:  Kimberly S Butler; Paul N Durfee; Christophe Theron; Carlee E Ashley; Eric C Carnes; C Jeffrey Brinker
Journal:  Small       Date:  2016-01-18       Impact factor: 13.281

3.  In vivo Targeting of Liver Cancer with Tissue- and Nuclei-Specific Mesoporous Silica Nanoparticle-Based Nanocarriers in mice.

Authors:  Ziqiang Ding; Dujin Wang; Wei Shi; Xiaomei Yang; Siliang Duan; Fengzhen Mo; Xiaoqiong Hou; Aiqun Liu; Xiaoling Lu
Journal:  Int J Nanomedicine       Date:  2020-10-29

Review 4.  Membrane mimetic surface functionalization of nanoparticles: methods and applications.

Authors:  Jacob Weingart; Pratima Vabbilisetty; Xue-Long Sun
Journal:  Adv Colloid Interface Sci       Date:  2013-05-02       Impact factor: 12.984

Review 5.  Ligand-targeted theranostic nanomedicines against cancer.

Authors:  Virginia J Yao; Sara D'Angelo; Kimberly S Butler; Christophe Theron; Tracey L Smith; Serena Marchiò; Juri G Gelovani; Richard L Sidman; Andrey S Dobroff; C Jeffrey Brinker; Andrew R M Bradbury; Wadih Arap; Renata Pasqualini
Journal:  J Control Release       Date:  2016-01-06       Impact factor: 9.776

Review 6.  Current trends in the use of liposomes for tumor targeting.

Authors:  Pranali P Deshpande; Swati Biswas; Vladimir P Torchilin
Journal:  Nanomedicine (Lond)       Date:  2013-09       Impact factor: 5.307

7.  Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice.

Authors:  Huan Meng; Meiying Wang; Huiyu Liu; Xiangsheng Liu; Allen Situ; Bobby Wu; Zhaoxia Ji; Chong Hyun Chang; Andre E Nel
Journal:  ACS Nano       Date:  2015-03-31       Impact factor: 15.881

Review 8.  Understanding the mechanisms of silica nanoparticles for nanomedicine.

Authors:  Ziyuan Li; Yingwen Mu; Cheng Peng; Martin F Lavin; Hua Shao; Zhongjun Du
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2020-06-29

9.  Construction of A Triple-Stimuli-Responsive System Based on Cerium Oxide Coated Mesoporous Silica Nanoparticles.

Authors:  Jia Wen; Kui Yang; Yongqian Xu; Hongjuan Li; Fengyu Liu; Shiguo Sun
Journal:  Sci Rep       Date:  2016-12-12       Impact factor: 4.379

10.  Lipid-Coated Mesoporous Silica Nanoparticles for the Delivery of the ML336 Antiviral to Inhibit Encephalitic Alphavirus Infection.

Authors:  Annette E LaBauve; Torri E Rinker; Achraf Noureddine; Rita E Serda; Jane Y Howe; Michael B Sherman; Amy Rasley; C Jeffery Brinker; Darryl Y Sasaki; Oscar A Negrete
Journal:  Sci Rep       Date:  2018-09-18       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.